CVN424

DRUG3 trials

Sponsors

Cerevance Beta Inc., Cerevance Beta, Inc.

Conditions

HealthyParkinson DiseaseParkinson's Disease

Phase 1

Study of CVN424 in Healthy Subjects

CompletedNCT03657030

Cerevance Beta, Inc.Healthy

Start: 2018-09-18End: 2019-05-30Updated: 2019-07-23

Relative Bioavailability and Food Effect Study of CVN424

CompletedNCT05635461

Cerevance Beta, Inc.Parkinson's Disease

Start: 2022-10-09End: 2022-11-21Updated: 2024-09-19

Phase 2

Phase 2, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of CVN424 in Parkinson’s Disease Patients with Motor Complications

RecruitingCTIS2024-516811-25-00

Cerevance Beta Inc.Parkinson Disease

Start: 2025-05-15Target: 148Updated: 2026-01-12

Related Papers

A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease

Journal of Pharmacology and Experimental Therapeutics2022-02-0217 citations